{"filings":[{"id":3625636,"accession_number":"0001493152-26-048139","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-10-22T21:29:23+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Glucotrack raises $2M via 22% OID secured convertible notes and sets 1-for-2 reverse split","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $2.56M principal of 8% senior secured convertible notes due 9 months for $2.0M cash, a 22% original issue discount; default rate 18%.","Notes convert at lower of $0.6390 or 80% of 15-day VWAP, floor 20% of Nasdaq Minimum Price; exchange cap 19.99% pending stockholder approval.","Issued warrants for 8,025,360 shares at $1.5975, exercisable 5 years; Dawson James got 7% cash fee, 160,508 warrants at 125% of conversion price, up to $50K expenses.","1-for-2 reverse split effective Oct 26, 2026; outstanding shares fall from 2,368,237 to about 1,184,119; new CUSIP 45824Q879.","Reverse split aims to regain Nasdaq $1.00 bid compliance by Nov 9, 2026, after prior 1-for-15 split on Aug 28, 2026; delisting possible if terms not met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3540997,"accession_number":"0001493152-26-047582","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-10-19T20:05:22+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Glucotrack issues 406,198 new warrants at $7.50 after holders waive issuance and VRT restrictions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Glucotrack's Oct. 13, 2026 waiver with Requisite Holders ends the 90-day equity issuance restriction and warrant variable-rate price adjustment from the July 14, 2026 purchase agreement.","In exchange, Glucotrack will issue New Warrants for 406,198 common shares at $7.50 per share; they expire in five years and carry a 9.99% beneficial ownership cap.","The New Warrants are not exercisable until stockholders approve the Warrant Shares under Nasdaq Listing Rule 5635; the exercise price has customary adjustments with a 20% closing-price floor.","The equity-issuance waiver covers all Holders, while the variable-rate exercise-price waiver applies only to Existing Warrants held by Holders that signed; other transaction documents remain in force."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3431596,"accession_number":"0001493152-26-046847","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K/A","filed_at":"2026-10-13T20:45:18+00:00","items":["9.01"],"status":"ready","headline":"Glucotrack restates Lokahi merger pro forma for 1-for-15 reverse split; H1 2026 pro forma net loss $19.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Lokahi merger closed July 14, 2026; 5,323,013 common-equivalent shares issued, valued at $33.33M ($6.261/share).","Purchase price allocated to $25.4M in-process R&D/intangibles and $14.67M goodwill; liabilities assumed $9.24M.","Pro forma H1 2026 net loss $19.70M (no revenue); FY2025 pro forma net loss $28.14M, EPS loss $236.97.","Bridge: $4.45M gross (face $5.71M, 22% OID, 8% coupon, due 4/14/27) plus $3.5M follow-on (due 5/4/27).","1-for-15 split effective Aug 28, 2026; ELOC allows up to $50M of stock sales over 3 years, none sold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3128716,"accession_number":"0001493152-26-044657","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-09-28T21:29:13+00:00","items":["1.01","9.01"],"status":"ready","headline":"Glucotrack ends variable-floor adjustments on Bridge/September warrants; Bridge Notes repaid Sept 25","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bridge Warrant Amendment, Amendment No. 2 to Common Warrant and September Warrant Amendment each remove provisions permitting downward adjustment to the Floor Price.","September Note Amendment (effective Sept 28, 2026 after all holders signed) makes the Floor Price an absolute floor below which no conversion or Conversion Price adjustment may occur.","September Note Amendment also requires any True-Up Amount make-whole payment to be satisfied only in cash.","Bridge Notes from the July 14, 2026 securities purchase agreement (joinder Aug 4, 2026) with Bridge Investors were repaid in full on Sept 25, 2026 at the registered direct offering close.","Bridge Warrant amendments began Sept 22, 2026 and execution remains ongoing; each is effective on execution by the Company and the applicable holder."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3074598,"accession_number":"0001493152-26-044182","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-09-24T21:15:26+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Glucotrack announces $3.1M public offering of 169,388 shares at $2.04 and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 169,388 common shares at $2.04 plus pre-funded warrants for 1,350,220 shares at $2.039.","Gross proceeds expected ~$3.1M; net proceeds to repay existing debt, remainder for working capital.","Placement agent Dawson James Securities; 8% cash fee; closing expected Sept 25, 2026.","Directors/officers subject to 90-day lock-up; company restricted on new equity issuances for 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3028876,"accession_number":"0001493152-26-043844","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-09-23T13:21:42+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack (Lōkahi) advances LT-100, submits protocol; ai² platform flags 45 assets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed strategic business combination on July 14, 2026; Glucotrack Technologies now wholly owned subsidiary.","LT-100 for osteoarthritis knee pain: clinical protocol submitted for regulatory review; targeting near-term study start.","Planned study evaluates once-weekly subcutaneous injection vs historical 15 weekly intradermal injections.","ai² platform has 14 university partners, screening 12,000+ abandoned late-stage programs; 45 assets met initial criteria.","Qare first ai² Accelerator initiative; business model aims to monetize assets before registration trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2963796,"accession_number":"0001493152-26-043389","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-09-18T21:10:19+00:00","items":["5.02","9.01"],"status":"ready","headline":"Glucotrack director Paul V. Goode resigns citing potential conflict of interest","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul V. Goode resigned from Glucotrack board effective Sept. 14, 2026.","Resignation cites potential conflict between company and subsidiary under Lokahi Therapeutics merger agreement.","Company provided resignation notice as Exhibit 17.1; Goode may file disagreement letter.","CEO Erik Emerson signed the 8-K; no replacement director named.","Conflict relates to implementing duties, rights, and obligations of entities in the merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2853236,"accession_number":"0001493152-26-042582","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-09-14T20:15:37+00:00","items":["1.01","5.07","9.01"],"status":"ready","headline":"Glucotrack stockholders approve ELOC and bridge note share issuances","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Special meeting Sep 11, 2026: quorum 3,661,960 shares (34.61% of 10,578,822 outstanding).","Proposal 1 (ELOC with White Lion Capital): 3,101,374 for, 228,374 against, 332,212 abstentions — approved.","Proposal 2 (Bridge Notes/Warrants): 3,106,894 for, 226,850 against, 328,216 abstentions — approved.","Adjournment proposal not presented because Proposals 1 and 2 passed.","Sep 14, 2026 amendment to Common Warrants requires stockholder approval before exercise per Nasdaq Listing Rule 5635(d)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2826156,"accession_number":"0001493152-26-042428","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-09-11T21:20:19+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Glucotrack raises $11.6M convertible notes: $4.5M cash, rollover of existing notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $11,596,172.68 in senior secured convertible notes: $4.5M cash plus $4,545,014.69 rollover; 22% original issue discount.","Notes bear 8% interest, mature in 9 months; conversion at lower of $3.12 or 80% of 15-day VWAP, with 20% floor.","Investors received warrants to buy 4,831,739 shares at $7.50/share (5-year term); exchange cap 19.99% pending stockholder approval.","Dawson James sold as sole placement agent; 7% cash fee plus 148,668 placement agent warrants (125% of conversion price).","Registration statement due in 10 days; penalty shares $250k per 30-day delay, capped at $1.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2771196,"accession_number":"0001493152-26-041978","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-09-09T21:00:13+00:00","items":["1.01","2.03","3.02"],"status":"ready","headline":"Glucotrack settles Alto debt dispute with $2M cash and $2M convertible note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement with Alto resolves ~$10.9M asserted debt from Apimeds Pharmaceuticals; Glucotrack and others jointly liable.","Pays $2.0M initial cash, issues $2.0M convertible note (5% interest, quarterly $500k payments from Nov 30, 2026 to Aug 31, 2027), plus up to $125k legal fees.","Note convertible into GCTK common at $2.98/share, subject to 9.99% beneficial ownership cap and Nasdaq limits.","Alto's release effective upon full payment; default triggers acceleration and increased interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2550197,"accession_number":"0001493152-26-040653","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-08-28T21:15:19+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Glucotrack completes 1-for-15 reverse stock split; shares drop to ~798,144","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective Aug 28, 2026 at 4:30 PM ET; every 15 shares became 1 share.","Outstanding shares reduced from 11,972,157 to ~798,144; authorized shares unchanged at 250M.","Split-adjusted trading begins Aug 31, 2026; ticker stays GCTK; new CUSIP 45824Q887.","Approved by stockholders at Aug 18, 2026 annual meeting; fractional shares round up.","Outstanding stock options/warrants adjusted proportionally with corresponding exercise price changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2548676,"accession_number":"0001493152-26-040600","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K/A","filed_at":"2026-08-28T20:28:40+00:00","items":["9.01","2.01"],"status":"ready","headline":"Glucotrack's Lokahi acquisition target: $53K cash, $8.1M H1 loss, going concern doubt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Lokahi had $53,186 cash and no revenue as of June 30, 2026; total assets $2.5M vs liabilities $9.2M.","H1 2026 net loss of $8.1M; R&D expense $1.86M, G&A $4.1M, interest expense $2.16M.","Accumulated deficit $8.8M; shareholders' equity deficit $6.7M as of June 30, 2026.","Independent auditor raised substantial doubt about Lokahi's ability to continue as a going concern.","Cash used in operations $3.6M for six months ended June 30, 2026; no committed financing source."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2503317,"accession_number":"0001493152-26-040332","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-08-27T12:44:31+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack announces 1-for-15 reverse stock split effective Aug 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-15 reverse split effective at market open Aug 31, 2026; shares cut from 11,972,157 to ~798,144.","Split aims to regain Nasdaq $1.00 minimum bid compliance; must hold closing bid ≥$1.00 through Nov 9, 2026.","Stockholders approved split at Aug 18, 2026 annual meeting; no fractional shares, rounding up to whole share.","New CUSIP 45824Q887; symbol GCTK unchanged on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2337956,"accession_number":"0001493152-26-039143","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-08-19T13:00:33+00:00","items":["5.07"],"status":"ready","headline":"Glucotrack shareholders approve 1:30 reverse split and warrant inducement at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected; votes for ranged 934,050-961,363; ~1.67M broker non-votes.","Say-on-pay approved: 962,623 for, 122,785 against, 33,960 abstain.","Ratification of CBIZ CPAs P.C. as auditor: 2,621,952 for, 134,874 against.","Reverse stock split up to 1:30 approved: 2,099,338 for, 674,484 against.","Warrant inducement approved: 895,306 for, 138,265 against, 85,797 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2162206,"accession_number":"0001493152-26-036858","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-08-10T20:05:28+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Glucotrack amends White Lion ELOC: issues 2.5M commitment shares, adds true-up provision","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment dated Aug 7, 2026 to July 14, 2026 ELOC with White Lion Capital, LLC.","Company to issue 2,505,513 commitment shares within 1 business day after registration statement effectiveness.","New true-up clause: if Commitment Fee Price < Minimum Price, Company owes up to $1,000,000 minus effective amount within 120 days after Measurement Date.","Issuance exempt under Section 4(a)(2) and Rule 506(b); shares fully earned on effective date.","All other terms of the ELOC Purchase Agreement remain in full force and effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2081356,"accession_number":"0001493152-26-036218","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-08-05T21:20:30+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Glucotrack raises $5.5M in combined equity and convertible debt financing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$2.0M equity PIPE at $0.75/unit: each unit includes one share (or pre-funded warrant) and a 5-year warrant at $1.50.","$3.5M follow-on bridge convertible debt with 8% interest, 9-month maturity, and 22% original issue discount.","Conversion and warrant exercise require stockholder approval; conversion price is lower of Nasdaq minimum or 80% of VWAP.","Proceeds to strengthen balance sheet and provide growth capital for portfolio execution.","E.F. Hutton & Co. served as exclusive advisor to Lōkahi Therapeutics, a Glucotrack subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1970476,"accession_number":"0001493152-26-035503","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-07-30T21:29:16+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack subsidiary Lokahi advances LT-100 to single-injection strategy after FDA meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lokahi Therapeutics (GCTK subsidiary) plans to simplify LT-100 from 15 intradermal injections to a single subcutaneous injection per visit.","Type C meeting with FDA in May 2026 supported the proposed clinical strategy for LT-100.","Nonclinical minipig study showed subcutaneous administration achieved systemic exposure consistent with prior intradermal data.","Clinical evaluation of single-injection approach expected to begin as early as Q4 2026, with initial readout in H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1942998,"accession_number":"0001493152-26-035242","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K/A","filed_at":"2026-07-29T21:15:26+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Glucotrack enters exchange agreement to convert $900K promissory note into common stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Partitioned $900K note from existing $3.6M promissory note; balance of original note reduced accordingly.","Exchange shares to be issued at Minimum Price (lower of July 24 closing or 5-day average); delivery by Aug 31, 2026.","Exchange under Section 3(a)(9) of Securities Act; no additional cash consideration or commissions paid.","Beneficial ownership limitation of 9.99% applies; shares may be issued in tranches if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1886920,"accession_number":"0001493152-26-034815","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-07-27T20:30:22+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Glucotrack enters exchange agreement to convert $900K note into common stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On July 22, 2026, Glucotrack partitioned a $900,000 promissory note from an existing $3.6M note (reduced by prior exchanges).","Investor may exchange portions of the Partitioned Note for common stock at the lower of closing price or 5-day average.","No cash consideration; exchange shares issued under Section 3(a)(9) exemption; beneficial ownership limited to 9.99%.","Original Note remains in effect with reduced balance; Partitioned Note extinguished upon full exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1666877,"accession_number":"0001493152-26-033393","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-07-15T21:20:18+00:00","items":["1.01","2.01","2.03","3.02","5.01","5.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Glucotrack completes reverse merger with Lokahi; existing holders get 10% floor","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Lokahi shareholders receive 90% of fully diluted equity; existing Glucotrack holders get at least 10%.","CEO Paul Goode resigns; Erik Emerson appointed CEO and board member effective July 14, 2026.","Bridge financing of $4.45M via senior secured convertible notes and warrants closed same day.","Subsidiary contribution of $7M to Operating Sub for diabetes business, released in installments.","Post-closing: proxy statement for stockholder approval and Nasdaq listing of conversion shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":472076,"accession_number":"0001493152-26-023889","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-05-15T20:45:37+00:00","items":["3.01","9.01"],"status":"ready","headline":"Glucotrack receives second Nasdaq delisting notice; plans to appeal by May 18","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First notice on May 11: non-compliance with minimum bid price of $1.00.","Second notice on May 15: stockholders' equity below $2.5M; additional delisting basis.","Company intends to request hearing by May 18 to appeal both deficiencies.","No assurance of success; stock (GCTK) faces potential delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":445196,"accession_number":"0001493152-26-023202","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-05-14T21:27:11+00:00","items":["2.02","9.01"],"status":"ready","headline":"Glucotrack Q1 net loss $4.3M, IDE submitted to FDA for implantable CGM","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.3M vs $6.8M YoY; cash $3.9M as of March 31, 2026.","Submitted Investigational Device Exemption (IDE) to FDA for fully implantable CBGM; targeting U.S. clinical trial launch in 2H 2026.","Reduced promissory note from $3.6M to ~$1.6M via stock exchange; drew $1.0M under equity line post-quarter.","R&D expenses $2.1M, G&A $2.1M; cash runway expected into early 3Q 2026.","Peer-reviewed data in IEEE Sensors and J. Diabetes Research show sensor stability and 6.8% MARD over 240 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93279,"accession_number":"0001493152-26-021706","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack submits IDE to FDA for US clinical study of implantable CBGM","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Glucotrack submitted an IDE application to the FDA to initiate a US clinical study of its fully implantable continuous blood glucose monitoring (CBGM) system.","CBGM is designed for 3-year sensor longevity, blood-based accuracy, and no on-body wearable component.","Company plans to proceed with US clinical study following FDA review and approval of the IDE.","IDE submission follows years of preclinical evaluation and iterative engineering; data support advancing to clinical evaluation.","CEO Paul Goode stated the submission reflects progress toward offering a discreet, accurate CGM option for diabetes patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93278,"accession_number":"0001493152-26-020747","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Glucotrack converts $988k note into 1.3M shares, reduces debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged a $988k partitioned promissory note for 1,300,000 common shares with an existing investor.","No cash or other consideration paid by the investor; debt reduction with no immediate cash outlay.","Beneficial ownership limitation at 19.9% may cause the exchange to occur in tranches.","Shares issued under Section 3(a)(9) exemption as exchange for outstanding securities.","Company also released an updated investor presentation furnished as Exhibit 99.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93277,"accession_number":"0001493152-26-019788","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack publishes peer-reviewed study showing CBGM accuracy MARD 6.8% over 240 days in ovine model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study in Journal of Diabetes Research shows weighted average MARD of 6.8% across 79 IV glucose tolerance tests in ovine model.","34 devices implanted in 17 sheep; no device-related adverse events observed over up to 240 days.","Results support path to IDE submission with FDA for further clinical development toward commercialization.","Prior first-in-human study demonstrated MARD of 7.7% with 99% data capture and no serious adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93276,"accession_number":"0001493152-26-016507","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Glucotrack exchanges $600K promissory note for 895,000 common shares in debt-to-equity swap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partitioned $600K from $3.6M original note and exchanged it for 895K shares of common stock.","Exchange done under Section 3(a)(9) exemption; no cash or other consideration paid by investor.","Issuance subject to 19.9% beneficial ownership limitation; shares may be issued in tranches.","Original note reduced by $600K, otherwise remains in full force.","Holding period of original note (Sept 2025) tacks to exchange shares for Rule 144 purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104764,"accession_number":"0001493152-26-013654","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Glucotrack reports FY2025 net loss $19.4M; cash $7.4M; plans IDE filing Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2025 was $19.4M, down from $22.6M in 2024; no product revenue.","Cash and equivalents $7.4M at Dec 31, 2025, up from $5.6M; raised $4.0M private placement in Dec 2025.","R&D expenses $9.8M vs $9.5M; G&A $6.3M vs $5.1M year-over-year.","Expects to file IDE with FDA in Q2 2026 to start US clinical feasibility study of implantable CBGM in H2 2026.","Believes existing cash sufficient only through Spring 2026 to fund IDE submission and trial initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104763,"accession_number":"0001493152-26-013095","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack to file IDE with FDA for implantable CBGM in Q2 2026, citing positive trial results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Brazil first-in-human study (Dec 2024-Jan 2025) showed MARD 7.7%, 99% data capture, and zero serious adverse events.","Australia feasibility study started July 2025; findings are incorporated for planned US trial.","Three US patents issued Oct/Nov 2025 covering sensor chemistry, intravascular lead, and low-power electronics.","Expects to file IDE with FDA in Q2 2026 and initiate US clinical study in H2 2026, pending approval.","Reinforced commercial foundation: market research, reimbursement pathway, dual-source manufacturing, seasoned leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104762,"accession_number":"0001493152-26-010049","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Glucotrack shareholders approve stock issuances for ELOC and warrants; ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Votes: ELOC proposal: 126,610 for, 18,261 against, 7,846 abstain, 293,631 non-votes.","Warrant issuance proposal: 26,134 for, 18,151 against, 7,841 abstain, 293,631 non-votes, 100,591 excluded shares.","Auditor ratification passed overwhelmingly: 431,871 for, 4,108 against, 10,369 abstain.","Quorum was 44.1% (446,348 of 1,011,279 shares outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104761,"accession_number":"0001493152-26-004158","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack receives USPTO approval for three CBGM patents","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three US patents issued by USPTO: US 12,453,494 (Oct 28, 2025), US 12,458,257 and US 12,458,258 (Nov 4, 2025).","Patents protect proprietary sensor chemistry, intravascular lead design, and low-power electronics for the CBGM platform.","The patents strengthen Glucotrack's competitive position and IP protection as it advances its implantable CBGM toward commercialization.","Glucotrack's CBGM is a long-term implantable device with up to 3-year sensor longevity, no wearable component, and direct blood glucose measurement.","The system measures glucose from blood, aiming to provide real-time readings with less lag than interstitial fluid sensors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121042,"accession_number":"0001493152-25-029791","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Glucotrack raises $4.0M via private placement of pre-funded and common warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.0M from sale of 1,033,591 pre-funded warrants and 2,067,182 common warrants at $3.87/unit.","Common warrants exercise price $3.87, not exercisable until stockholder approval, expire 5 years after approval.","Net proceeds for working capital and general corporate purposes.","Officers and directors entered 90-day lock-up agreements restricting share transfers.","Curvature Securities acted as sole placement agent; receives 7% cash fee and warrants for 124,030 shares at $4.257."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121041,"accession_number":"0001493152-25-029216","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack issues investor presentation; no material details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Issued an investor presentation on December 29, 2025.","Filing text contains no financial or operational specifics.","Presentation content was not included in the 8-K exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121040,"accession_number":"0001493152-25-022305","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Glucotrack reports Q3 net loss of $4.2M; cash $7.9M to fund through Q1 2026; IDE submission Spring 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net loss $4.2M ($4.64 per share) vs $5.1M in Q3 2024; nine-month net loss $15.8M.","Cash and equivalents $7.9M at Sep 30, 2025; expected to fund operations through first quarter 2026.","Secured $3M convertible note ($3.6M principal) and $20M ELOC; proceeds to repay note and eliminate warrant dilution.","IDE submission for CBGM to FDA expected Spring 2026; long-term feasibility study initiated in Australia."],"consensus_eps_estimate":null,"consensus_eps_actual":30.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121039,"accession_number":"0001493152-25-021320","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":[],"status":"ready","headline":"Glucotrack special meeting adjourned and cancelled due to lack of quorum","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Only 17.6% of 158,370 outstanding shares were represented at reconvened meeting on Nov 7, 2025.","Meeting was permanently adjourned and cancelled because quorum was not achieved.","This follows an earlier adjournment on Oct 31, 2025 for the same reason.","No proposals were voted on; no business was conducted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121038,"accession_number":"0001493152-25-020992","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":[],"status":"ready","headline":"Glucotrack special meeting adjourned due to lack of quorum; reconvenes Nov 7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Only 16.4% of outstanding shares (899,410 total) were represented, failing to constitute a quorum.","Adjournment proposal approved: 136,928 votes for, 8,655 against, 1,923 abstain.","Meeting adjourned to November 7, 2025 at 12:00 p.m. ET to solicit additional proxies for the Issuance Proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121037,"accession_number":"0001493152-25-020607","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack reconvenes special meeting Nov 7 for vote on $20M equity purchase with Sixth Borough Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting reconvenes November 7, 2025 at 12 p.m. ET to vote on Equity Purchase Agreement with Sixth Borough Capital Fund LP.","Agreement allows issuance of more than 20% of outstanding common stock for up to $20 million under NASDAQ Rule 5635(d).","Record date for voting is September 23, 2025; Board unanimously recommends voting FOR all proposals.","Shareholders can vote by telephone, online, or by returning proxy card; assistance available via Sodali & Co."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121036,"accession_number":"0001493152-25-020072","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack adds Dr. Usman Latif to clinical advisory team for integrated glucose monitoring","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appoints Usman Latif, MD, MBA, a neuromodulation and PDN expert, to its clinical advisory team.","Dr. Latif is Associate Professor at Kansas University Medical Center and board-certified anesthesiologist.","Company aims to integrate glucose sensing into spinal cord stimulator leads for PDN patients.","PDN affects ~1 in 5 Americans with diabetes, over 7 million people.","Long-term preclinical study completed showing feasibility and safety of epidural glucose monitoring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121035,"accession_number":"0001493152-25-019834","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack reminds shareholders to vote on Oct 31 special meeting for equity purchase with Sixth Borough Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting on October 31, 2025 at 12 p.m. ET; record date is September 23, 2025.","Proposal concerns an Equity Purchase Agreement with Sixth Borough Capital Fund.","Board unanimously recommends voting 'FOR' all proposals; proxy statement filed Oct 3.","Shareholders encouraged to vote by telephone, online, or proxy; help via Sodali & Co."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137670,"accession_number":"0001493152-25-013290","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Glucotrack issues $3.6M convertible note at $3M price; ELOC proceeds to repay","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $3.6M convertible promissory note for $3M purchase price ($600K OID), no interest, due in 12 months or upon Qualified Financing.","Conversion price floor of $4.87/share; converts into equity of next financing raising ≥$5M.","Simultaneously entered $20M ELOC with Sixth Borough Capital; 100% of ELOC net proceeds repay note pre-stockholder approval, 50% post.","Note is unsecured, no restrictive covenants; standard events of default include bankruptcy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137669,"accession_number":"0001493152-25-013094","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Glucotrack signs up to $20M equity purchase agreement with Sixth Borough Capital Fund","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investor committed to buy up to $20M of common stock over 24 months at company's discretion.","Regular purchase price at 97% of VWAP; add-on/intraday at 95% of VWAP.","Commitment fee of 1.5% ($300k) payable in cash, stock, or warrants on Commencement Date.","Exchange cap of 179,792 shares (19.99% of outstanding) unless stockholder approval or price condition met.","Investor prohibited from short sales; company may terminate pact with 1 business day notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137668,"accession_number":"0001493152-25-011975","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Glucotrack H1 net loss $11.6M; cash $9.6M; on track to implant first CBGM patients in Australia Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.6M for H1 2025 vs $7.4M prior year; operating expenses rose $0.9M.","Cash and equivalents $9.6M as of June 30, 2025, expected to fund operations through 2025.","Received ethical approval in Australia; first patient implants in multicenter feasibility study expected Q3 2025.","Repurchased Series A warrants, eliminating warrant liability accounting and dilution overhang.","Positive first-in-human CBGM data reported: MARD 7.7%, 99% data capture, no serious adverse events."],"consensus_eps_estimate":null,"consensus_eps_actual":34.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137667,"accession_number":"0001493152-25-011630","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack appoints David S. Hirsh, MD as Medical Director, Cardiology","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Hirsh, a cardiac electrophysiologist, joins Glucotrack's clinical advisory team for its CBGM program.","He will oversee clinical and educational initiatives supporting the CBGM's intravascular placement approach.","Glucotrack is advancing its CBGM through a long-term OUS early feasibility study and upcoming US pilot study.","CBGM is a long-term implantable system measuring glucose directly from blood, with up to 3-year sensor life."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137666,"accession_number":"0001493152-25-011509","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack to exhibit CBGM at ADCES; touts progress toward US pilot study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Presenting at ADCES Annual Meeting Aug 8-11, 2025 in Phoenix, AZ; CBGM at Booth #1724.","Poster: 'Endocrinologists’ Perspectives on an Implantable CBGM' on Aug 9, 12:00-1:00 PM MST.","Preparing to begin long-term early feasibility study after successful initial clinical validation.","CBGM is fully implantable, lasts up to 3 years, measures blood glucose directly with no on-body wearable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137663,"accession_number":"0001493152-25-011423","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K/A","filed_at":"2025-07-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Glucotrack dismisses Grant Thornton Israel as auditor, engages CBIZ CPAs effective July 18, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissal effective July 18, 2025; Grant Thornton reports for past two years included going-concern explanatory paragraph but no adverse opinion.","No disagreements on accounting principles or practices; material weaknesses in internal controls previously disclosed.","Audit committee engaged CBIZ as successor independent registered public accounting firm for FY 2025.","Grant Thornton provided letter dated July 25, 2025, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137665,"accession_number":"0001493152-25-011386","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Glucotrack dismisses Grant Thornton, engages CBIZ as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved dismissal of Fahn Kanne & Co. Grant Thornton Israel and engagement of CBIZ CPAs P.C., effective July 18, 2025.","Grant Thornton's reports for FY2024 and FY2023 included a going-concern explanatory paragraph but were otherwise unqualified.","No disagreements with Grant Thornton on accounting principles or audit scope during FY2024, FY2023, or subsequent interim period.","Material weaknesses in internal control over financial reporting previously disclosed (IT controls, accounting personnel, segregation of duties) were discussed with Grant Thornton.","Company will file Grant Thornton's response letter by amendment within two business days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137664,"accession_number":"0001641172-25-018104","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack repurchases ~49,700 Series A warrants, cuts potential dilution","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Repurchased over 90% of Series A Warrants on June 30, 2025 for cash on hand in a negotiated transaction.","Approximately 4,300 Series A Warrants remain outstanding; company expects to buy back most of those.","Series B Warrants had been previously extinguished in exchange for common stock as of March 31, 2025.","Buyback eliminates warrant liability accounting and reduces future share dilution overhang."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155043,"accession_number":"0001641172-25-016387","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack reports positive final first-in-human CBGM study results with MARD 7.7%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study met all endpoints; MARD 7.7% across 122 matched pairs, 99% data capture, no serious adverse events.","92% of readings in green zone of Diabetes Technology Society Error Grid, none in unsafe zones.","Ten participants with Type 1 or Type 2 diabetes; device implanted via subclavian vein, monitored 4 days.","Glucotrack expects to initiate long-term early feasibility study in Q3 2025.","OneTwo Analytics applied AI/ML analytics to validate performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155042,"accession_number":"0001641172-25-015194","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Glucotrack executes 1-for-60 reverse stock split effective June 13, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split approved by stockholders on May 22; reduces outstanding shares from 34,047,337 to ~567,456.","No fractional shares issued; rounding up to next whole share for odd lots.","Ticker remains GCTK; split-adjusted trading begins June 16, 2025; new CUSIP 45824Q804.","Historical per-share net loss recast: FY2024 post-split basic loss $4,101.94 vs pre-split $68.44.","Q1 2025 post-split basic loss $40.14 vs pre-split $0.67; share count adjusted accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155041,"accession_number":"0001641172-25-014803","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack announces 1-for-60 reverse stock split effective June 16, 2025 to meet Nasdaq bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-60 reverse stock split approved by shareholders on May 22, 2025, effective at market open on June 16, 2025.","Outstanding shares reduced from ~32.5M to ~542,356; no fractional shares issued, rounding up to next whole share.","Reverse split intended to bring GCTK into compliance with Nasdaq $1.00 minimum bid price requirement.","Company warns it may be delisted if it becomes deficient on any Nasdaq rule before September 29, 2025.","CUSIP changes to 45824Q804; trading symbol remains GCTK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155040,"accession_number":"0001641172-25-013543","cik":1506983,"company_name":"Glucotrack, Inc.","ticker":"GCTK","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Glucotrack to present first-in-human CBGM data at ADA 85th Scientific Sessions","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Will present safety & performance data from first-in-human trial of implantable continuous blood glucose monitor (CBGM).","Live presentation by CSO Mark Tapsak on June 21 in Innovation Hub; poster session June 22.","CBGM measures glucose directly from blood, lasts up to 3 years, no on-body wearable.","Company preparing for next clinical phase (long-term feasibility study)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3961497.9543171115,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-06-04T23:59:59+00:00|155040"}